U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820333) titled 'Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer' on Jan. 16.
Brief Summary: The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods. As a result, 18F-PSMA-1007 (Radelumin(R)) was approved in Germany and several EU countries, most recently in Germany in 01/2024, for use in primary staging of high-risk prostate cancer and re-staging in the context of biochemical recurrence (BCR). This could be seen as a milestone in the management of prostate cancer and will significa...